WO2016074641A8 - Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用 - Google Patents

Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用 Download PDF

Info

Publication number
WO2016074641A8
WO2016074641A8 PCT/CN2015/094502 CN2015094502W WO2016074641A8 WO 2016074641 A8 WO2016074641 A8 WO 2016074641A8 CN 2015094502 W CN2015094502 W CN 2015094502W WO 2016074641 A8 WO2016074641 A8 WO 2016074641A8
Authority
WO
WIPO (PCT)
Prior art keywords
nadh
salt
health care
care product
preparing drug
Prior art date
Application number
PCT/CN2015/094502
Other languages
English (en)
French (fr)
Other versions
WO2016074641A1 (zh
Inventor
傅荣昭
张琦
刘月梅
Original Assignee
邦泰生物工程(深圳)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 邦泰生物工程(深圳)有限公司 filed Critical 邦泰生物工程(深圳)有限公司
Priority to US15/311,790 priority Critical patent/US20170095500A1/en
Publication of WO2016074641A1 publication Critical patent/WO2016074641A1/zh
Publication of WO2016074641A8 publication Critical patent/WO2016074641A8/zh
Priority to US15/618,934 priority patent/US9950000B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

烟酰胺腺嘌呤二核苷酸(NADH)或其盐在制备治疗苯丙酮尿症的药物或保健品中的应用，其中所述NADH或其盐的单剂量为1~100 mg。
PCT/CN2015/094502 2014-11-14 2015-11-13 Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用 WO2016074641A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/311,790 US20170095500A1 (en) 2014-11-14 2015-11-13 Use of nadh or salt thereof in preparation of drugs or health-care products for treating phenylketonuria
US15/618,934 US9950000B2 (en) 2014-11-14 2017-06-09 Use of NADH or salt thereof in preparation of drugs or health-care products for treating phenylketonuria

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410644152.5 2014-11-14
CN201410644152.5A CN104352513B (zh) 2014-11-14 2014-11-14 Nadh或盐在制备治疗苯丙酮尿症药物或保健品的应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/311,790 A-371-Of-International US20170095500A1 (en) 2014-11-14 2015-11-13 Use of nadh or salt thereof in preparation of drugs or health-care products for treating phenylketonuria
US15/618,934 Continuation US9950000B2 (en) 2014-11-14 2017-06-09 Use of NADH or salt thereof in preparation of drugs or health-care products for treating phenylketonuria

Publications (2)

Publication Number Publication Date
WO2016074641A1 WO2016074641A1 (zh) 2016-05-19
WO2016074641A8 true WO2016074641A8 (zh) 2016-10-20

Family

ID=52519886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/094502 WO2016074641A1 (zh) 2014-11-14 2015-11-13 Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用

Country Status (3)

Country Link
US (2) US20170095500A1 (zh)
CN (1) CN104352513B (zh)
WO (1) WO2016074641A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104352513B (zh) * 2014-11-14 2017-04-05 邦泰生物工程(深圳)有限公司 Nadh或盐在制备治疗苯丙酮尿症药物或保健品的应用
WO2019028877A1 (zh) * 2017-08-11 2019-02-14 邦泰生物工程(深圳)有限公司 一种含有nadh和nadph的组合物及其应用
CN109893510A (zh) * 2019-02-28 2019-06-18 合肥康诺药物开发有限公司 一种辅酶i肠溶片及其制备方法
CN110638826A (zh) * 2019-10-09 2020-01-03 泓博元生命科技（深圳）有限公司 Nadh和/或nmn在制备肌肉增强或抑制肌肉量下降的药物或保健品中的应用
CN110638827A (zh) * 2019-10-17 2020-01-03 泓博元生命科技（深圳）有限公司 Nadh及其盐在制备皮肤色素抑制剂中的应用
CN110664830A (zh) * 2019-10-24 2020-01-10 泓博元生命科技（深圳）有限公司 Nadh及其盐在制备防治咽炎的药物或保健品中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360421B (zh) * 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
KR20120039121A (ko) * 2010-10-15 2012-04-25 고려대학교 산학협력단 Ｎａｄｈ를 유효성분으로 하는 근육 피로 회복 또는 근육강화용 조성물 및 그 방법
CN103462003A (zh) * 2013-08-13 2013-12-25 甘肃华羚生物技术研究中心 苯丙酮尿症病患者专用特膳食品
CN104352513B (zh) * 2014-11-14 2017-04-05 邦泰生物工程(深圳)有限公司 Nadh或盐在制备治疗苯丙酮尿症药物或保健品的应用

Also Published As

Publication number Publication date
CN104352513B (zh) 2017-04-05
CN104352513A (zh) 2015-02-18
WO2016074641A1 (zh) 2016-05-19
US9950000B2 (en) 2018-04-24
US20170304346A1 (en) 2017-10-26
US20170095500A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
WO2016074641A8 (zh) Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
WO2015134808A3 (en) Probiotic formulations and methods for use
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
SA517390475B1 (ar) نظام أكياس متعددة وطريقة لتحضير مكونات الدم
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
WO2015130547A8 (en) Bis-cyclic guanidine compound compositions, methods of use and treatment thereof
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016023980A3 (en) Process for manufacturing a customizable medical device and device obtained by said process
EP3137071A4 (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
WO2016082807A3 (zh) 伊曲康唑的新用途
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases
EP3411088C0 (en) IMPLANTABLE MEDICAL PRODUCTS, PROCESS FOR THEIR MANUFACTURE AND THEIR USE
PH12016502113A1 (en) Drug for treatment of tinnitus patients
AU2017900807A0 (en) Medical exfoliation - the product, the process, ideas, reasons for use, treatment and therapeutic use.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15858592

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15311790

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15858592

Country of ref document: EP

Kind code of ref document: A1